A considerable variety of chemotherapy regimens in first- and second-line therapy of patients with advanced or metastatic GC was observed; however, conformity was seen in the most frequently selected regimens.

Administration and acquisition of chemotherapy comprised the majority of costs; the frequent use of regimens including capecitabine may reflect a conscious move of doctors towards cost-saving measures.